Dallas, Texas 07/31/2013 (Financialstrend) – Stereotaxis, Inc. (NASDAQ:STXS) announced that its Vdrive Robotic Navigation System with V-Sono(TM) Intracardiac Echocardiography catheter manipulator got approval to market in United States from Food and Drug Administration (FDA) with a grant of 510(k) clearance, following this announcement the company surged a great height with the increase in shares by 228.65% at the end of yesterday. This Vdrive Robotic Navigation System with V-Sono shows remote control of compatible ICE catheters introduced into the right atrium, it was first released in the year 2011 in Europe, where over 2,000 clinical cases has utilized this Vdrive system in which V-Sono disposable is utilized in 100 clinical cases.
Stereotaxis Board Chairman and Interim Chief Executive Officer, William Mills said “This approval is definitely a great milestone for our company, this Vdrive Robotic Navigation System with V-Sono should add significance to clinical value in our U.S as it has already done in Europe, we also look forward to open up an expanding, untapped electrophysiology (EP) market where ICE catheters are extensively used.
Stereotaxis, Inc. (NASDAQ:STXS) had closed for the day on Tuesday with $5.85 per share with a bullish behavior of 228.65% over the previous day’s closing price. The intraday movements of the stock were between low values of $2.33 to a high value of $6.90 per share. The yearly stock price variations are between the lower values of $1.01 to a higher value of $6.90 per share. The shares held by the investors and the company insider’s account to 8.15 million with an institutional ownership of 53%. The total stock value of the company in the stock market is $47.7 billion. The trading trend of the company for its latest trading day was 15.38 million shares compared to the average trading volume over the month of 29.315 million shares.